Details of the Company's participation can be found below:
Format: Company presentation and one-on-one investor meetings
Date:
Time:
Webcast: https://wsw.com/webcast/cantor12/ettx/2120370
The webcast of the Company's presentation will be accessible in the News & Events section of the Entasis website at https://www.entasistx.com/.
About Entasis
Entasis is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. Entasis' pathogen-targeted design platform has produced a pipeline of product candidates, including sulbactam-durlobactam (targeting Acinetobacter baumannii infections), zoliflodacin (targeting Neisseria gonorrhoeae infections), ETX0462 (targeting multiple Gram-negative pathogens including Pseudomonas aeruginosa) and ETX0282CPDP (targeting Enterobacteriaceae infections). For more information, visit www.entasistx.com.
Contact:
T: (781) 810-0114
E: kyle.dow@entasistx.com
Investor
T: (929) 469-3859
E: bmackle@lifesciadvisors.com
(C) 2021 Electronic News Publishing, source